{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:06:42Z","timestamp":1770066402043,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kissei Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13104-018-3483-6","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T08:09:23Z","timestamp":1528445363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-4735","authenticated-orcid":false,"given":"Hisato","family":"Shima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Miya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Minakuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/00041552-200111000-00003","volume":"10","author":"GA Block","year":"2001","unstructured":"Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens. 2001;10:741\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3483_CR2","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"3483_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119\u201327.","journal-title":"JAMA"},{"key":"3483_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1681\/ASN.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova T, Guti\u00e9rrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:388\u201396.","journal-title":"J Am Soc Nephrol"},{"key":"3483_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","volume":"60","author":"AA Lopes","year":"2012","unstructured":"Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, et al. Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60:90\u2013101.","journal-title":"Am J Kidney Dis"},{"key":"3483_CR6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.bone.2006.12.062","volume":"40","author":"S Fukumoto","year":"2007","unstructured":"Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism\u2014unique biological characteristics of FGF23. Bone. 2007;40:1190\u20135.","journal-title":"Bone"},{"key":"3483_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3483_CR8","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/ndt\/gfq089","volume":"25","author":"MM Nasrallah","year":"2010","unstructured":"Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:2679\u201385.","journal-title":"Nephrol Dial Transplant"},{"key":"3483_CR9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/ndt\/gfn571","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"3483_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584\u201392.","journal-title":"N Engl J Med"},{"key":"3483_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/nep.12891","volume":"22","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology. 2017;22:293\u2013300.","journal-title":"Nephrology"},{"key":"3483_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.jrn.2017.02.007","volume":"27","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Long-term assessment of the safety and efficacy of PA21 (sucroferric oxyhydroxide) in Japanese hemodialysis patients with hyperphosphatemia: an open-label, multicenter, phase III study. J Ren Nutr. 2017;27:346\u201354.","journal-title":"J Ren Nutr"},{"key":"3483_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638\u201347.","journal-title":"Kidney Int"},{"key":"3483_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30:1037\u201346.","journal-title":"Nephrol Dial Transplant"},{"key":"3483_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5414\/CN109021","volume":"88","author":"DW Coyne","year":"2017","unstructured":"Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88:59\u201367.","journal-title":"Clin Nephrol"},{"key":"3483_CR16","first-page":"1330","volume":"32","author":"AC Covic","year":"2017","unstructured":"Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017;32:1330\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"3483_CR17","first-page":"515606","volume":"2015","author":"O Phan","year":"2015","unstructured":"Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, Burnier M. Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failure. Biomed Res Int. 2015;2015:515606.","journal-title":"Biomed Res Int"},{"key":"3483_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247\u201388.","journal-title":"Ther Apher Dial"},{"key":"3483_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Renal Replace Ther. 2017;3:36.","journal-title":"Renal Replace Ther"},{"key":"3483_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40265-017-0758-5","volume":"77","author":"WLS Peter","year":"2017","unstructured":"Peter WLS, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ. A review of phosphate binders in chronic kidney disease: incremental Progress or just higher costs? Drugs. 2017;77:1155\u201386.","journal-title":"Drugs"},{"key":"3483_CR21","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478\u201383.","journal-title":"N Engl J Med"},{"key":"3483_CR22","first-page":"S1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1\u2013201.","journal-title":"Am J Kidney Dis"},{"key":"3483_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793\u2013803.","journal-title":"J Bone Miner Res"},{"key":"3483_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tem.2012.07.002","volume":"23","author":"N Bhattacharyya","year":"2012","unstructured":"Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012;23:610\u20138.","journal-title":"Trends Endocrinol Metab"},{"key":"3483_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2174\/1389200216666150206124424","volume":"15","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab. 2014;15:953\u201365.","journal-title":"Curr Drug Metab"},{"key":"3483_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/1744-9987.12155","volume":"18","author":"T Akizawa","year":"2014","unstructured":"Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, Tomino Y, et al. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial. 2014;18:404\u201313.","journal-title":"Ther Apher Dial."},{"key":"3483_CR27","doi-asserted-by":"publisher","first-page":"e50295","DOI":"10.1371\/journal.pone.0050295","volume":"7","author":"KL Kuo","year":"2012","unstructured":"Kuo KL, Hung SC, Lin YP, Tang CF, Lee TS, Lin CP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE. 2012;7:e50295.","journal-title":"PLoS ONE"},{"key":"3483_CR28","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1681\/ASN.2012121164","volume":"24","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24:1151\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"3483_CR29","doi-asserted-by":"publisher","first-page":"f4822","DOI":"10.1136\/bmj.f4822","volume":"347","author":"E Litton","year":"2013","unstructured":"Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822.","journal-title":"BMJ"},{"key":"3483_CR30","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","volume":"26","author":"K Umanath","year":"2015","unstructured":"Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"3483_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.ajkd.2013.11.015","volume":"64","author":"AA Yusuf","year":"2014","unstructured":"Yusuf AA, Weinhandl ED, St Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in medicare part D. Am J Kidney Dis. 2014;64:95\u2013103.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-3483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-018-3483-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-3483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T19:14:36Z","timestamp":1559934876000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-018-3483-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1186\/s13104-018-3483-6","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"363"}}